Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (32)
Ghayas C. Issa
Branko Cuglievan
Georgina El Hajjar
1The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States
Wei Ying Jen
Alex Bataller
2Division of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Nicholas J. Short
1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Courtney D. DiNardo
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA
Yesid Alvarado
1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States
Sanam Loghavi
Dzifa Yawa Duose
Baili Zhang
1The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States
Ken Furudate
1The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States
Jing Ning
Lianchun Xiao
Elie Mouhayar
MD Anderson Cancer Center, Houston, Texas, United States
Alessandro Pinto
Aram Bidikian
3Yale University, Department of Internal Medicine, Section of Hematology, New Haven, United States
Erika Thompson
7The University of Texas MD Anderson Cancer Center, Genetics, Houston, United States
Naval Daver
1The University of Texas MD Anderson Cancer Center, Houston, TX
Guillermo Garcia-Manero
Aziz Farhat
2Division of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
David McCall
1Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
Tapan M. Kadia
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA
Hussein A. Abbas
M D Anderson Cancer Center, Houston, Texas, United States
Sheila Tan
Alexandre Bazinet
1The University of Texas MD Anderson Cancer Center, Houston, United States
Elias Jabbour
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA
Guillermo Montalban-Bravo
Farhad Ravandi
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA
Koichi Takahashi
Michael Andreeff
1Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Hagop M. Kantarjian
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA